This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Almac are pleased to announce the launch of their novel “Direct to Patient” shipping service for clinical trials recognising the shift in market trends to introduce as many efficiencies as possible into the management of clinical trials and the supply chain.
The Direct to Patient offering further enhances the existing clinical trial distribution service provided by Almac by co-ordinating all clinical trial (including temperature and non-temperature controlled) material shipments from clinical sites directly to patient’s homes throughout the US and Canada. Due diligence has been performed to ensure adherence with US federal, state and Canadian regulations.
This service offers clinical trial patients enhanced flexibility as it works around their personal convenience and improves the patient experience by reducing on-site clinic visits. In addition patients no longer have to travel to clinical sites for all of their visits thereby reducing associated costs and drop-out rates.
The Direct to Patient service implemented by Almac is in response to increasing sponsor demand and enables trial sponsors to move closer to the patients participating in the trials, regardless of their proximity to study sites.
Donna Christopher, Global VP Operations at Almac commented “Our innovative direct to patient solution offers sponsors a flexible and cost effective approach to conduct their clinical trials which improves patient experience, compliance and efficiency whilst reducing the burden associated with patient retention. We firmly believe this addresses significant challenges currently experienced by our sponsors and Almac are delighted to offer this as part of our established clinical supply solutions.”
Find out more about Almac’s Direct to Patient service – http://almacgroup.com/clinical-trial-supply/global-distribution-and-supply-chain-management/direct-to-patient
